These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33507738)

  • 21. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using ChEMBL web services for building applications and data processing workflows relevant to drug discovery.
    Nowotka MM; Gaulton A; Mendez D; Bento AP; Hersey A; Leach A
    Expert Opin Drug Discov; 2017 Aug; 12(8):757-767. PubMed ID: 28602100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
    Greiwe J; Honsinger R; Hvisdas C; Chu DK; Lang DM; Nicklas R; Apter AJ
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3057-3063. PubMed ID: 36064185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
    Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
    Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ChEMBL bioactivity database: an update.
    Bento AP; Gaulton A; Hersey A; Bellis LJ; Chambers J; Davies M; Krüger FA; Light Y; Mak L; McGlinchey S; Nowotka M; Papadatos G; Santos R; Overington JP
    Nucleic Acids Res; 2014 Jan; 42(Database issue):D1083-90. PubMed ID: 24214965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity, assay and target data curation and quality in the ChEMBL database.
    Papadatos G; Gaulton A; Hersey A; Overington JP
    J Comput Aided Mol Des; 2015 Sep; 29(9):885-96. PubMed ID: 26201396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Collation and data-mining of literature bioactivity data for drug discovery.
    Bellis LJ; Akhtar R; Al-Lazikani B; Atkinson F; Bento AP; Chambers J; Davies M; Gaulton A; Hersey A; Ikeda K; Krüger FA; Light Y; McGlinchey S; Santos R; Stauch B; Overington JP
    Biochem Soc Trans; 2011 Oct; 39(5):1365-70. PubMed ID: 21936816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Use of Social Media in Detecting Drug Safety-Related New Black Box Warnings, Labeling Changes, or Withdrawals: Scoping Review.
    Lee JY; Lee YS; Kim DH; Lee HS; Yang BR; Kim MG
    JMIR Public Health Surveill; 2021 Jun; 7(6):e30137. PubMed ID: 34185021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
    Omae K; Onishi A; Sahker E; Furukawa TA
    JAMA Netw Open; 2022 Sep; 5(9):e2230973. PubMed ID: 36083581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SuperDRUG2: a one stop resource for approved/marketed drugs.
    Siramshetty VB; Eckert OA; Gohlke BO; Goede A; Chen Q; Devarakonda P; Preissner S; Preissner R
    Nucleic Acids Res; 2018 Jan; 46(D1):D1137-D1143. PubMed ID: 29140469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
    Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
    Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
    Walgren JL; Mitchell MD; Thompson DC
    Crit Rev Toxicol; 2005; 35(4):325-61. PubMed ID: 15989140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
    Mostaghim SR; Gagne JJ; Kesselheim AS
    BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
    [No Abstract]   [Full Text] [Related]  

  • 39. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs.
    Wang LM; Wong M; Lightwood JM; Cheng CM
    Ann Pharmacother; 2010 Jan; 44(1):28-34. PubMed ID: 20040698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.